HOTH THERAPEUTICS INC (HOTH)

Company Profile

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is also focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer; a treatment for mast-cell derived cancers and anaphylaxis; a treatment for traumatic brain injury and ischemic stroke, and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases. The company also has assets being developed for atopic dermatitis; a treatment for asthma and allergies using inhalational administration, and a treatment for acne as well as inflammatory bowel diseases. The company is also developing a diagnostic device via a mobile device. Its development products include HT-001, HT-KIT, HT-TBI and HT-ALZ. Its preclinical development products include HT-003, HT-004, and HT-002. The company also has interests in certain other assets being developed by third parties, including a treatment for patients with lupus.

Company Info

HOTH THERAPEUTICS INC

1 Rockefeller Plz Ste 1039

New York City NEW YORK 10020

P: 15515782261

CEO: Robb Knie

Employees: 2

Website: https://hoththerapeutics.com/